Skip to main content

Table 1 Baseline characteristics of participants by treatment at randomization

From: Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

  All (n = 51) Glibenclamide (n = 23) Acarbose (n = 28) P value
Gender (female, %) 51.0% 56.5% 46.4% 0.477
Age (years) 53.7 ± 8.2 54.7 ± 8.3 52.8 ± 8.2 0.378
Disease duration (years) 6.9 ± 4.6 6.0 ± 4.7 7.6 ± 4.5 0.106
BMI (kg/m2) 25.6 ± 3.3 25.3 ± 3.8 25.9 ± 3.0 0.334
HbA1c (%) 8.4 ± 1.2 8.6 ± 1.6 8.2 ± 0.8 0.691
Fasting plasma glucose (mmol/l) 8.5 ± 2.3 9.0 ± 3.0 8.2 ± 1.3 0.538
DI30 41.1 ± 25.0 36.8 ± 19.1 44.7 ± 29.0 0.247
DI120 57.3 ± 28.6 51.2 ± 24.2 62.5 ± 31.4 0.289
HOMA-IR 3.7 ± 2.9 4.7 ± 3.9 2.9 ± 1.5 0.316
MISI 3.4 ± 1.8 3.2 ± 1.7 3.6 ± 1.8 0.321
HOMA-β (%) 44.9 ± 40.4 52.3 ± 49.7 38.9 ± 30.4 0.248
Insulinogenic index30 (pmol/mmol) 42.1 ± 63.4 35.0 ± 37.2 47.9 ± 79.0 0.416
  1. Chi-square test. Mann–Whitney U test. Data are presented as mean ± standard deviation or percentage of participants.
  2. DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index; HOMA-IR, homeostasis model assessment insulin resistance index; MISI, Matsuda insulin sensitivity index.